Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022877 | 0.90 | KMT2A (0.67) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15023481 | 0.89 | LMNA (0.67) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15022735 | 0.88 | KMT2A (0.48) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15033610 | 0.88 | ALDH1A1 (0.67) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15022957 | 0.87 | LMNA (0.50) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15023508 | 0.85 | ALDH1A1 (0.63) | KMT2ALMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL15033623 | 0.83 | ALDH1A1 (0.47) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15033637 | 0.83 | GAA (0.59) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15038327 | 0.82 | ALDH1A1 (0.55) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15023269 | 0.81 | ALDH1A1 (0.61) | LMNASMN1; SMN2ALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | CASE WESTERN RESERVE UNIVERSITY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION | IAPP, APP, BACE1 | KMT2A 4787/4885LMNA 737/4885SMN1; SMN2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.